All posts by medical

Assistant Professor in Cognitive Neuroscience, PSYC21-52 job with DURHAM UNIVERSITY | 243068 – Times Higher Education (THE)

The Department of Psychology at Durham University seeks to appoint talented individuals to the role of Assistant Professor. In the current call, we welcome applications from those with research and teaching interests in the broad field of Cognitive Neuroscience. This post offers an exciting opportunity to make a major contribution to the development of internationally excellent research and teaching while allowing you unrivalled opportunities to progress and embed your career in an exciting and progressive institution. For more information, please visit our Department pages at https://www.dur.ac.uk/psychology/

The Cognitive Neuroscience group benefits from cutting-edge cognitive neuroscience research facilities including a 3T fMRI scanner (and a 0T mock scanner for piloting and training purposes), excellent facilities for rodent behavioural neuroscience, neurostimulation facilities, EEG, state of the art mobile and lab-based eye tracking, whole body motion capture, immersive virtual reality, a molecular diagnostics lab, sound attenuated rooms, a fully equipped molecular diagnostics laboratory, patient testing facilities and access to high-performance computing facilities. The group leads on impact and engagement around blindness, stroke and dementia with strong links to the NHS and clinically relevant populations. For more information about our research visit https://www.dur.ac.uk/psychology/research/groups/cognitive/.

The Department of Psychology is an internationally recognised centre of research excellence and interdisciplinarity across the breadth of psychological and behavioural science. We are currently ranked in the top 100 of Psychology Departments world-wide according to the QS World Rankings. The department's research groupings reflect our major areas of activity: Cognitive Neuroscience, Developmental Science, & Quantitative Social Psychology. Each group also leads a taught Masters programme, alongside a prestigious undergraduate programme in Psychology and a new undergraduate programme in Behavioural Science, extending our research strengths into the next generation. In addition, the department houses a number of University Research Centres which bring in staff from across the department, university, and region to focus on key research issues. The department's broad approach to the discipline places it in an excellent position to take advantage of emerging opportunities and challenges and our collegiate approach allows staff to work across research areas to provide novel solutions to global problems.

Durham University is one of the world's top universities with strengths across the Arts and Humanities, Sciences and Social Sciences. The University sits in a beautiful historic city where it shares ownership of a UNESCO World Heritage Site with Durham Cathedral. A collegiate University, Durham recruits outstanding students from across the world and offers an unmatched wider student experience. Less than 3 hours north of London, an hour and a half south of Edinburgh, and ten minutes from the centre of Newcastle, County Durham is a region steeped in history and natural beauty. Close to the Northumberland National park and coastline, the Durham Dales, including the North Pennines Area of Outstanding Natural Beauty, our University is situated within truly breath-taking scenery and local attractions.

More:
Assistant Professor in Cognitive Neuroscience, PSYC21-52 job with DURHAM UNIVERSITY | 243068 - Times Higher Education (THE)

University of Maryland Launches New Brain and Behavior Institute, Announces Founding Director – PR Web

Elizabeth Quinlan, Biology Professor at the University of Maryland

COLLEGE PARK, Md. (PRWEB) January 27, 2021

University of Maryland Senior Vice President and Provost Mary Ann Rankin announced last week the establishment of the new Brain and Behavior Institute (BBI) and appointed its founding director, UMD Biology Professor Elizabeth Quinlan.

The BBI will elevate the universitys research and teaching programs in neuroscience and promote innovative, multidisciplinary approaches to solve the most pressing problems of nervous system function and disease. A primary goal of the institute is to strengthen collaborations among neuroscientists, engineers, computer scientists, mathematicians, physical scientists, cognitive scientists and humanities scholars.

"Understanding the brain and how it influences behavior is one of the most important and complicated grand challenges of our time, and our success ultimately depends on teamwork, said Amitabh Varshney, dean of UMDs College of Computer, Mathematical, and Natural Sciences (CMNS). "By establishing this new institute and appointing a strong leader who has experience with interdisciplinary research, our BBI faculty members will be able to build on their strengths and work together across their diverse fields, lending expertise and support to each others efforts, and take our university's high-quality neuroscience research program to the next level."

For the past five years, UMD invested in the Brain and Behavior Initiative to foster interdisciplinary interactions in neuroscience across its College Park campus, and the provosts announcement of the new institute renews and expands the universitys commitment to neuroscience research and teaching. At the heart of the initiative was a desire for a collaborative research community across the physical and life sciences. The initiatives seed grant program yielded a 900% return on seed grant investments, through 15 awards from private organizations and government funding, including the National Institutes of Health (NIH) BRAIN Initiative, National Institute of Mental Health, National Science Foundation, and Air Force Office of Scientific Research.

The institute will play a vital role in the universitys neuroscience ecosystem, which also includes the Neuroscience and Cognitive Science interdisciplinary graduate program and new undergraduate neuroscience major launched last fall. The BBI will also continue to strengthen interactions with collaborators at other institutions, including the University of Maryland, Baltimore (UMB).

A campus-wide endeavor, the BBI is administratively housed in CMNS and supported financially by the Office of the Provost, UM Center for Economic and Entrepreneurship Development, A. James & Alice B. Clark Foundation, Division of Research, CMNS, A. James Clark School of Engineering, College of Behavioral and Social Sciences, School of Public Health, College of Education, and College of Arts and Humanities.

The BBI will recruit outstanding faculty, tools, and partnerships to expand and elevate interdisciplinary research and training in neuroscience, Quinlan said. By strengthening and diversifying interactions between neuroscience and complementary disciplines, the BBI is positioning UMD to be a world leader in advancing innovations in experimental and analytical approaches to understanding the brain and behavior.

As the institute director, Quinlan will hold the Clark Leadership Chair in Neuroscience, which was endowed with a gift from the A. James & Alice B. Clark Foundation that was matched by the states Maryland E-Nnovation Initiative Fund. Quinlan also has a joint appointment in the Department of Anatomy and Neurobiology at UMB.

In her own research program, Quinlan's research has identified changes in the brain that occur with aging and pioneered strategies to promote recovery of functions lost with age. The research in her lab has been continuously funded by the NIH since 2002.

Quinlan served as co-director of the Brain and Behavior Initiative and the MPowering the State initiative on Brain Health and Human Performance from 2018 to 2020. In the latter role, she strengthened collaborative neuroscience research and graduate education between UMD and the University of Maryland School of Medicine. From 2007 to 2016, she directed the physiological systems concentration area of the Biological Sciences Graduate Program.

She joined UMD in 2001 as an assistant professor, following postdoctoral fellowships at Brown University and the University of Virginia. Quinlan earned a Ph.D. in biological sciences from the University of Illinois at Chicago and a B.S. in psychology/biology from the University of Iowa.

She incorporates a highly interdisciplinary approach to neuroscience in both classroom and lab settings, Rankin said of Quinlan in her announcement. I have no doubt that she will advance the rising profile of Maryland neuroscience research and promote the success of the BBI community.

Share article on social media or email:

See the rest here:
University of Maryland Launches New Brain and Behavior Institute, Announces Founding Director - PR Web

$25 million gift to Brown will fuel innovation in brain science – Brown University

PROVIDENCE, R.I. [Brown University] A new $25 million gift to Brown University will fuel scientific discovery and help innovative new ideas in brain science get off the ground.

The generous gift from a donor who wishes to remain anonymous will support research in computational brain science, enabling Brown to attract and retain world-class teachers and scholars, and it will endow an innovation awards program at the Universitys Robert J. and Nancy D. Carney Institute for Brain Science to provide seed funding for new high-impact research in computation and other areas of brain science.

This transformational gift recognizes the momentum that continues to build at Brown University, where our talented faculty are leading scientific discovery including in the rapidly emerging specialty of computational brain science, said Diane Lipscombe, director of the Carney Institute and a professor of neuroscience. This gift will allow us to sustain a culture of innovation, which has led to an impressive number of discoveries and returned countless new grants to Brown that forge new areas of research.

Professor of Neuroscience David Berson prepares a microscope stage for fluorescence imaging and recording of electrical activity. Berson received an innovation award in 2018 for a project to develop methods for faster, more accurate and more versatile segmentation software for electron-microscopic analysis.

With more than 180 affiliated faculty members in 20 units and eight affiliated graduate programs, the Carney Institute is pursuing research that has real-life, human applications, Lipscombe said. Core areas of research include work on innovative advances in computational brain science to investigate cognition, behavior and mood disorders; novel technologies to interface with the brain to understand brain circuits and restore lost functions; and research into the mechanisms of cell death to identify therapies for neurodegeneration, such as in amyotrophic lateral sclerosis (ALS) and Parkinsons and Alzheimers diseases.

This new $25 million gift is part of the Universitys $3-billion BrownTogether campaign, which has raised $2.74 billion to date. It also builds upon significant philanthropic investment in Browns cutting-edge work in brain science of the total contributed by donors to date, more than $187 million has been raised to support research and education in brain science, including a $100 million gift that named the institute in 2018. The gifts support a core research priority in Browns Building on Distinction strategic plan: understanding the human brain.

In 2014, the Carney Institute launched an innovation awards program to support early-stage research projects that are too new to attract external funding but have great potential to advance science and benefit society. The new gift will endow a similar innovation awards program, ensuring that the Carney Institute will be able to sustainably invest in innovation for years to come.

Ashley Webb, an assistant professor of molecular biology, cell biology and biochemistry at Brown, received an innovation award in 2019 to establish a new system to study how neurons age. She is developing a cell reprogramming platform, called direct reprogramming, to study aging in the hypothalamus brain region. The hypothalamus controls critical processes, such as sleep, temperature regulation, eating and metabolism, which can become dysregulated with aging. With direct reprogramming, Webb is able to convert a skin cell, for example, into a brain cell that maintains the hallmarks of aging.

From studying genes and circuits, to healthy behavior and psychiatric disorders, Carney Institute faculty produce insights and tools to see, map, understand and fix problems in the nervous system.Aging is the greatest risk factor for a number of diseases, including neurodegenerative diseases such as Alzheimers, Webb said. If we understand whats going wrong during aging, this will give us important insight into the mechanisms of disease. But right now, we dont have very good systems for studying these diseases in the context of aging. This is the problem we are working to solve.

Starting from mouse skin cells, Webbs group generated rare hypothalamic brain cells, called POMC neurons, that are important for metabolic health and weight control. Normally, these cells trigger satiety (the feeling of being full), but they lose the ability to do so as they age.

Webb is now applying the same approach to create POMC neurons from human cells, which for the first time will allow researchers to generate rare types of human neurons that are physiologically aged.

If we take cells from aged individuals, the neurons we generate actually retain damage associated with aging, Webb said. This allows us to compare young and aged neurons, and understand why the old neurons dont function as well. We believe this platform will give us important insight into why metabolism is altered with age and in many diseases.

The Innovation Awards Program, Webb said, gave her group the freedom to take on a bold, early-stage idea. Her team hopes to use the direct reprogramming approach to generate neurons from individuals with brain diseases and disorders, such as Alzheimers.

See the original post here:
$25 million gift to Brown will fuel innovation in brain science - Brown University

Musicians, Regardless of Innate Pitch Ability, Have More Connected Brains than Non-Musicians: Study | Neuroscience – Sci-News.com

A new study, published in the Journal of Neuroscience, suggests that long-term musical training is associated with robust changes in large-scale brain networks.

Increased subnetworks in absolute pitch musicians compared to non-musicians obtained in the whole-brain network-based statistic (NBS) analysis for resting-state functional connectivity (A) and diffusion weighted imaging (DWI)-based structural connectivity (B). Abbreviations: ACC anterior cingulate cortex; AP absolute pitch; aSMG anterior supramarginal gyrus; aSTG anterior superior temporal gyrus; cOp central operculum; fOp frontal operculum; FP frontal pole; HG Heschls gyrus; IFG, po inferior frontal gyrus, pars opercularis; L left; MTG middle temporal gyrus; PCC posterior cingulate cortex; postCG postcentral gyrus; preCG precentral gyrus; pSTG superior temporal gyrus, posterior division; pOp parietal operculum; PP planum polare; PT planum temporale; ptFG posterior temporal fusiform gyrus; R right; toFG temporal occipital fusiform gyrus; TP temporal pole. Image credit: Leipold et al., doi: 10.1523/JNEUROSCI.1985-20.2020.

Professional musicians are a popular model for investigating experience-dependent plasticity in human large-scale brain networks.

A minority of musicians with Mozart and Michael Jackson in their ranks possess absolute pitch, the ability to name a tone without reference. But, it remains unclear how this ability impacts the brain.

In the new research, Dr. Simon Leipold of Stanford University and colleagues compared the brains of professional musicians to non-musicians.

The study involved 153 female and male human participants: 52 absolute pitch musicians, 51 non-absolute pitch musicians, and 50 non-musicians.

To the teams surprise, there were no strong differences between the brains of musicians with and without absolute pitch ability; instead absolute pitch may shape the brain in more subtle ways.

Compared to non-musicians, both types of musicians had stronger functional connectivity the synchronized activity of brain regions in the auditory regions of both brain hemispheres.

Musicians also had stronger white matter connections between auditory regions and lobes involved in various types of high-level processing.

Musicians that began their training at a younger age had stronger structural connections than musicians with a later start.

These results demonstrate how experience shapes the brain, especially early in life, and how enhanced musical skills are represented in our brain.

We identified robust and replicable effects of musical expertise on intrinsic functional and structural brain networks, the researchers said.

As effects were stronger in the functional domain, we hypothesize that musical training particularly affects functional compared to structural networks.

The effects of absolute pitch on large-scale brain networks might be subtle, requiring very large samples or task-based experiments to be detected.

_____

Simon Leipold et al. Musical expertise shapes functional and structural brain networks independent of absolute pitch ability. Journal of Neuroscience, published online January 25, 2021; doi: 10.1523/JNEUROSCI.1985-20.2020

See the rest here:
Musicians, Regardless of Innate Pitch Ability, Have More Connected Brains than Non-Musicians: Study | Neuroscience - Sci-News.com

Brown University gets $25M to support brain research – Houston Chronicle

PROVIDENCE, R.I. (AP) Brown University has received a $25 million gift that will be used to invest in its cutting edge brain science research, the Ivy League school said in a statement.

The anonymous donation will support computational brain science and help the university attract and retain top scholars.

It will also endow an innovation awards program at Brown's Robert J. and Nancy D. Carney Institute for Brain Science to provide seed funding for new research in computation and other areas of brain science.

Computational neuroscience seeks to understand the functions of the brain at all levels from cells to cognition using principles from physics, mathematics, engineering, computer science, biology, cognitive science and psychology, the school said.

This gift will allow us to sustain a culture of innovation, which has led to an impressive number of discoveries and returned countless new grants to Brown that forge new areas of research, Diane Lipscombe, director of the Carney Institute and a professor of neuroscience, said in a statement Tuesday.

See original here:
Brown University gets $25M to support brain research - Houston Chronicle

Johns Hopkins, Mount Sinai turning to virtual rehab and video games to help patients recover from strokes – FierceHealthcare

The COVID-19 pandemic has brought experimentation in all different types of remote care, and that includes neuroscience. Physical therapists are exploring the use oftele-neurorehabilitation and gamification to help stroke victims recover.

JohnKrakauer, M.D., professor of neurology, neuroscience, and physical medicine and rehabilitation at the Johns Hopkins University School of Medicine, describes tele-neurorehabilitation as trying to use technology to beam yourself into the patient's home and give them that same kind of care without being present."

Usually that's going to require a mixture of a video hookup so that you can chat and watch what the patient is doing, and then varying degrees of gamification and instrumentation, said Krakauer, who also serves as chief medical and scientific adviser toMindMaze, an advanced neuroscience and digital therapeutics company.

3 Keys to the Future of CX in Healthcare

Cut to the chase with this quick-read outlining 3 consumer experience (CX) strategies payers can start using immediately to fuel better outcomes and drive more value in 2021.

People recovering from strokes need immediate guidance from physical therapists, and they are continuing this work remotely during the pandemic. Physical therapists direct patients on how to move while following along via video, such as directing patients to lift their arm up higher or move their foot in a certain way in repetition.

We know that immediate feedback about task performance is important, so we need people practicing at high intensity, said David Putrino, Ph.D., director of rehabilitation innovation for the Mount Sinai Health System, which uses MindMazes MindMotion Go platform to track body movements. We need someone watching closely saying that was a good movement and that was a not-so-good movement.

RELATED:AppliedVR testing the use of at-home virtual reality therapy for chronic pain

With hospitals in crisis from the influx of COVID patients, telerehabilitation fills a need to replace outpatient visits.

For many hospitals right now, it's simply not safe to attend outpatient visits, Putrino said. Its not advised. The hospitals are in crisis and managing an outpatient caseload is just not really something that is an important priority in terms of global safety for a lot of hospitals right now.

Following surgery, stroke victims would usually have a period of inpatient rehabilitation and then be discharged home. Following that, they required outpatient rehabilitation. Rather than patients simply accept their level of function without the outpatient therapy, providers are turning to tele-neurorehabilitation to continue their treatment.

This is really important because at the discharge point, you're still in your brain's critical period where therapy has a lot more of an effect on your long-term trajectory, Putrino said.

Physical therapists at Johns Hopkins Medicine clinic in Columbia, Maryland, are also using tele-neurorehabilitation to help patients address upper and lower dysfunction of extremities, according to Harrison Segal, a physical therapist at Johns Hopkins Hospital.

At our Johns Hopkins Hospital clinic in Columbia, we are utilizing gamified rehabilitation as a platform for evaluating and treating patients with neurological dysfunction, Segal said. The use of gamified rehabilitation through tele-neurorehabilitation allows us to see our patients at a higher frequency, improve their compliance with their home exercise program, and overall increase their dosage of exercise.

RELATED:Hinge Health scores $300M series D to expand digital musculoskeletal health solution

The University of California in San Francisco also plans to use the MindMaze technology as part of a clinical trial.

MindMazes MindMotion Go uses optical motion-capture technology to track the body movements of patients, according to Putrino. MindMotion Go consists of two components: One part tracks whole body movement and the other system can track hand movement, Putrino explained.

It can use computer vision to identify your body parts and track what your body parts are doing, Putrino said.

In 26 games, MindMaze lets you perform exercises to move the full body, arms, legs and trunk as well as create balance.

You can see a skeletal model of your body, which the therapist can also see, Krakauer said. You have a digitized version of your body on one side of the screen, you have the game on the screen, and you have the video link so the therapist can see the game and they can see you.

The MindMotion Go system includes a dashboard that lets healthcare professionals monitor a patients motor recovery process. The therapists help patients increase stride length and balance as well as grasping and reaching, according to Putrino.

Physical therapists track whether a patients arm motion and walking are improving. They create exercises for patients to work on remotely, and gamification is important to recovery. In fact, the games promote neuroplasticity, the process by which the brain recovers after neurons get damaged by a stroke.

What typically happens isthe brain finds a way to rewire itself around the existing damage so that it can continue to provide you with a similar level of function as before your stroke, Putrino said.

In the future, Putrino would like to see products such as MindMaze incorporate more sensors. He also sees a role for low-cost robotics in tele-neurorehabilitation. As the patient recovers it would gradually provide less assistance and allow the person to regain voluntary control over a limb, he said.

Going forward, the gamification elements of MindMaze can become more common for people that have experienced strokes and other neurological problems, according to Hayley Haaf, a physical therapist at Johns Hopkins Medicine in Lutherville, Maryland.

RELATED:Omada Health buys virtual physical therapy startup Physera for reported $30M

It will become more of our standard of care, including the use of gamified rehabilitation, to allow for standardized evaluations and treatments as well as improved patient compliance, Haaf said. It will also help to improve access to care, therefore allowing a greater number of patients to receive treatment.

In addition to stroke victims, tele-neurorehabilitation could help people with other types of conditions that restrict movement, according to Krakauer.

My guess is that we'll begin to see more and more use of technology to rehabilitate anyone with a neurological condition or some sort of immobility in general, Krakauer said. But in neurorehab, the big ones have been stroke and spinal cord injury, and to some degree, traumatic brain injury as well.

Putrino says the exercises in platforms like MindMaze can benefit people with neurological conditions that require motor rehabilitation, such as multiple sclerosis, Parkinsons disease, and spinal cord injury.

I think there's a lot of opportunity for the transference of the exercises to make sure that this can be helpful to as many patients as possible, hesaid.

Go here to see the original:
Johns Hopkins, Mount Sinai turning to virtual rehab and video games to help patients recover from strokes - FierceHealthcare

Neuroscience Antibodies and Assays Market Overview, Growth, Types, Applications, Market Dynamics, Companies, Regions, & Forecast to 2026 with key…

The Neuroscience Antibodies and Assays Market grew in 2019, as compared to 2018, according to our report, Neuroscience Antibodies and Assays Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Neuroscience Antibodies and Assays Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025.

Deep analysis about Neuroscience Antibodies and Assays Market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Neuroscience Antibodies and Assays Market

Get a Sample Copy of the Report at: https://i2iresearch.com/download-sample/?id=17508

The Neuroscience Antibodies and Assays Market is analysed based on product types, major applications and key players

Key product type:ConsumablesInstruments

Key applications:Pharmaceutical & Biotechnology CompaniesAcademic & Research InstitutesHospitals & Diagnostic Centers

Key players or companies covered are:Thermo FisherAbcamBio-RadMerckCell Signaling TechnologyGenscriptRockland ImmunochemicalsBioLegendSanta Cruz BiotechnologyRocheSiemens

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/need-customization/?id=17508

Key questions answered in the report:1. What is the current size of the Neuroscience Antibodies and Assays Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Neuroscience Antibodies and Assays Market?4. What is the likely market forecast & how will be Neuroscience Antibodies and Assays Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Neuroscience Antibodies and Assays Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

https://neighborwebsj.com/

Follow this link:
Neuroscience Antibodies and Assays Market Overview, Growth, Types, Applications, Market Dynamics, Companies, Regions, & Forecast to 2026 with key...

Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102 – BioSpace

Jan. 26, 2021 12:00 UTC

Funding Supports Aclipse Therapeutics and Sheffield Institute of Translational Neurosciences Development of M102 in Amyotrophic Lateral Sclerosis

RADNOR, Pa.--(BUSINESS WIRE)-- Aclipse Therapeutics (Aclipse or the Company), a private biopharmaceutical company, today announced that the Company and its collaborator, The Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK), were awarded a drug development research grant of 1.6 million (approximately US $2.2 million) from the UKs Medical Research Council (MRC), one of the largest funders of medical research worldwide, to support the translational development of M102. M102 is Aclipses drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also referred to as motor neuron disease (MND) or Lou Gehrigs disease.

M102 is a potentially disease-modifying drug candidate that has shown promise to impede ALS disease progression in a wide array of preclinical models. Currently, there is no cure for ALS and there are no effective treatments to halt or slow the progression of the disease.

This development funding from MRC is wonderful news for ALS/MND patients who are in dire need of an effective therapy to address this life-threatening neurodegenerative disease, stated Professor Dame Pamela Shaw, M.D., Director of SITraN and a primary contributor to M102s development program. Along with my SITraN colleagues, Dr. Richard Mead and Dr. Laura Ferraiuolo, we spearheaded the ALS/MND biology research that led to the development of M102, including the discovery of a potential precision medicine approach for M102 in ALS/MND, so we are very appreciative of MRCs funding support.

Aclipse is taking a multiple biological pathway, multiple disease mechanism approach to ALS. M102 activates the NRF2 (nuclear factor erythroid 2-related factor 2) and HSF1 (Heat shock factor 1) signaling pathways, which are recently understood to impact ALS pathophysiology. M102 is expected to be mechanistically superior to currently available drugs and may lead to significant slowing of disease progression in both familial and sporadic ALS.

The MRC grant will also support the development of patient stratification biomarkers that will be applied in the M102 clinical studies, potentially enabling a personalized medicine approach in ALS. The goal of the patient stratification biomarkers is to identify M102 drug responders versus non-responders in order to target M102 to those ALS patients most likely to benefit from the drug.

We greatly appreciate the support from MRC for our novel and broad multi-disease patho-mechanism approach to treating ALS patients, said Raymond K. Houck, CEO of Aclipse Therapeutics. The MRC award, coupled with our recent FightMND grant award, accelerates M102s development into its first-in-human clinical studies and validates M102s biology and potential for a precision medicine approach for the treatment of ALS.

The research funding from these programs will be key as they will support the completion of our investigational new drug (IND)-enabling work and the regulatory filings for first-in-human studies. Importantly, M102 may have applications in a wide array of conditions associated with impaired neuronal function such as Friedreichs ataxia, Huntingtons disease and Parkinsons disease, added Mr. Houck.

About ALS/MND Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a progressive neurodegenerative disease that affects motor neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. There is no cure and limited life-prolonging treatments for the disease. Based on U.S. population studies, approximately 5,600 people in the U.S. are diagnosed with ALS each year and as many as 25,000 Americans have the disease at any given time.

About Medical Research Counsel The United Kingdoms Medical Research Counsels mission is to improve human health through world-class medical research. To achieve this, MRC supports research across the biomedical spectrum, from fundamental lab-based science to clinical trials, and in all major disease areas. MRC works closely with the UKs National Health Service and the UK Health Departments to deliver its mission and give a high priority to research that is likely to make a real difference to clinical practice and the health of the population.

About the Sheffield Institute for Translational Neuroscience The Sheffield Institute for Translational Neuroscience (SITraN) is an international center of excellence recognized for its ground-breaking work in the fight against motor neurone disease and other common neurodegenerative disorders. SITraN brings together 300 staff and research students in multi-disciplinary teams with state-of-the-art laboratories and equipment to study neurological illness. The center is unique in its design to unite clinicians and multidisciplinary teams of scientists to translate discoveries in basic neuroscience into benefits for patients. The SITraN teams have developed a robust portfolio of in vitro and in vivo models to facilitate our understanding of disease mechanisms and identify new targets for therapeutic intervention which can be tested in our BRC experimental medicine programs.

The work of SITraN is a major pillar of the University of Sheffields cross-faculty Neuroscience Institute, one of four flagship research institutes launched in 2019 to tackle the biggest global challenges through pioneering real-world solutions and involving >120 principal investigators in the Faculties of Medicine, Science and Engineering.

About Aclipse Therapeutics Aclipse Therapeutics develops novel and differentiated drugs to treat orphan diseases with significant unmet medical needs. Our lead drug candidate, M102, is in development for the treatment of ALS with potential use in other neurodegenerative diseases such as Friedreichs ataxia, Huntington's disease and Parkinson's disease. M102 targets multiple disease pathomechanisms and enables a precision medicine approach for the identification of patients who are most likely to benefit from the drug. Aclipse has a very experienced orphan drug management team and a clinical advisory board of the top ALS physicians in the world. For more information about Aclipse, visit the website at https://www.aclipsetherapeutics.com or email info@aclipsetherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005044/en/

More here:
Aclipse Therapeutics Announces $2.2 Million Grant from UK's Medical Research Council for Development of M102 - BioSpace

Does the Ability To Think Depend on Consciousness? – Walter Bradley Center for Natural and Artificial Intelligence

The title question might seem like a strange one but it is vitally important if we are to interpret neuroscience correctly and if we are to understand the mindbrain relationship. In my view, the capacity for thought does not depend on consciousness. The term consciousness is at best meaningless and at worst an impediment to understanding the mind.

Consciousness is a very vague term and, ultimately, I dont think it has any useful meaning at all, apart from other categories such as sensation, perception, imagination, reason etc. Aristotle had no distinct term for it. Nor do I think did any of the ancient or medieval philosophers. Consciousness is a modern term that seems to subsume all of the sensate powers of the soul sensation, perception, sensus communis, imagination, memory, sensory appetite, etc.

What we usually mean when we use the term consciousness is arousal, which is a perceptual ability the state of being able to perceive. Arousal does indeed have a basis in neurophysiology it arises from activation of the reticular activating system deep in the brain. But arousal is merely increased potency for sensory perception, movement, memory, etc. We dont actually know what arousal means with regard to intellect, as distinct from memory and from behavioral markers. I will explain that in more detail below.

Of course, when you have impaired perception and memory, you have an impaired mental state. But what does that mean for other modalities like reason, will, etc.? Its a rather devilish and profound question: If you cant remember reasoning, does that mean that you didnt reason, or does it merely mean that you were simply unable to form memories while you were reasoning?

The difficulty in defining consciousness is well recognized in medicine. For example, I ask medical students and residents who report to me that a patient is unconscious to explain exactly what they mean. Do they mean sleeping, not moving, eyes are closed, or not answering questions? After all, patients who are in coma often move and even brain-dead patients usually have reflexes. If a patient is unconscious while sleeping, he may still be dreaming, in which case he is quite aware of his dream, and thus unconscious while asleep doesnt really mean unaware of everything, it just means unaware of some things.

This perennial problem with defining consciousness led to the development of the Glasgow Coma Scale (GCS) several decades ago. It has become the routine way that doctors describe consciousness. Patients are tested for three things: motor responses to stimuli, eye opening, and verbal responses, and they are assigned a numeral score according to a rubric. Full alertness (follows commands, opens eyes spontaneously, is verbally oriented to date and place) is 15. Brain death is 3. Mental status is always described in these terms a GCS of 8 (E2M4V2), for example, refers to a patient who opens his eyes only to noxious stimuli, moves in a non-purposeful way, and only makes grunting sounds. The GCS score is a meaningful and reproducible metric, whereas unconsciousness, because of its inherent ambiguity, is meaningless.

In medicine, the use of the terms conscious and unconscious is actually dangerous, because the vague meanings associated with these terms leads to miscommunication between physicians. A patient who is initially non-verbal and moves only by reflex who over time becomes quiet and unresponsive may be described in both states as unconscious. But the change may be a sign of impending catastrophe, and this change is not communicated unless specific details of the patients mental state are described. An unconscious patient in one bed may be sleeping. An unconscious patient in the next bed may be near brain death. The diagnosis of unconscious for both patients doesnt capture that difference.

When we speak of mental states, clarity and specificity are essential.

Another example will make the point even more clear. When I was a medical student, my anesthesiology professor said that the fundamental goals of good anesthesia are analgesia and amnesia. This shocked me: I asked him, What about unconsciousness? Doesnt anesthesia make patients unconscious during surgery? He replied that unconscious really has no medical meaning, and inability to feel pain and amnesia for the surgery are the only real measurable effects of anesthesia. We dont know and cant know if patients are conscious during surgery. We only know what behavior tells us: they show no physiological signs of pain and they have no memory of the event. The science of anesthesiology has nothing corresponding to unconscious it merely monitors and strives for analgesia and amnesia.

Here is a personal example: I had spinal anesthesia for ankle surgery a decade ago. I did not have general anesthesia. I was awake and speaking with the anesthesiologist throughout the operation but I felt no pain (from the spinal anesthetic) and I had no memory whatsoever of the procedure (from the sedative they gave me, which has strong amnestic effects). As far as I was concerned, it was the same as a general anesthetic I felt nothing and remember nothing. It was the same as being unconscious, which I was not. I was wide awake and conversing with the anesthesiologist (who is a friend of mine and reassured me that I said nothing embarrassing!). Without pain or memory, I was, for his purposes, unconscious, even though I was (they tell me) awake and talking the whole time. Subjectively I couldnt distinguish analgesia and amnesia from unconsciousness. So what does consciousness mean?

This has implications for our understanding of Adrian Owens remarkable research on persistent vegetative state. Owen took patients who had such severe brain damage that they were diagnosed as having no mental state at all they were vegetative and using MRI technology demonstrated that many of these patients are capable of quite complex thought, despite being in the deepest level of unconsciousness known to medicine, just one step above brain death.

There is nothing in psychology that corresponds to unconsciousness as a distinct state. There is unawareness of sensations, inability to form perceptions, inability to remember, etc. Consciousness per se is superfluous to the description of mental states, and actually obfuscates things.

Ive also had general anesthesia myself several times, and if you ask me whether I could reason and do mathematics and think about philosophy during general anesthesia, my only honest answer is I dont know. I dont remember doing those things, but then I dont remember talking to the anesthesiologist when I had spinal anesthesia. When you erase memory and erase behavioral response to stimulation, what basis is there for asserting extinction of the intellect?

Consciousness is just a proxy for a spectrum of mental states, and particularly implies a state of sensory arousal, capacity for memory, and capacity to move purposefully. The difficulty with using consciousness in philosophy and neuroscience is that impaired new memory formation, impaired perception and impaired behavior (i.e. impaired consciousness) does not preclude other mental states, such as the ability to recall old memories, to think abstractly, to experience emotions, etc. The ubiquitous example of this consciousness while unconscious is dreaming, in which very high levels of thought occur during deep sleep, which is what we would ordinarily call a state of deep unconsciousness.

When we describe mental states, we can only meaningfully use the terms that Aristotle applied to powers of the soul we need to ask about perceptual ability (can the patient see light, or hear sound), imagination (can the patient form mental images), memory, emotions, movement, or the use of reason. These are meaningful terms, and if we are in a state in which behavior and acquisition of new memories are extinguished, we have no basis for asserting that we have no other mental states during that time. As dreaming and the remarkable capacity for high-level thought in patients in persistent vegetative state demonstrate, unconscious people can have very complex mental states.

Consciousness adds nothing to the description of mental states. It is a meaningless term that too often misleads us, and it shouldnt be used in medicine, neuroscience, or philosophy.

You may also enjoy this article by Michael Egnor: Why critical theory might shape your life, going forward. Critical Theory has begun to rule the public square and we need to understand it.

Here is the original post:
Does the Ability To Think Depend on Consciousness? - Walter Bradley Center for Natural and Artificial Intelligence

January: Pesticides and sleep in bees and flies | News and features – University of Bristol

Just like us, many insects need a decent nights sleep to function properly, but this might not be possible if they have been exposed to neonicotinoid insecticides, the most common form of insecticide used worldwide, suggests research by academics at the University of Bristol.

Two studies by scientists at Bristols Schools of Physiology, Pharmacology and Neuroscience and Biological Sciences have shown these insecticides affect the amount of sleep taken by both bumblebees and fruit flies, which may help us understand why insect pollinators are vanishing from the wild.

Dr Kiah Tasman, Teaching Associate in the School of Physiology, Pharmacology and Neuroscience and lead author of the studies, said: "The neonicotinoids we tested had a big effect on the amount of sleep taken by both flies and bees. If an insect was exposed to a similar amount as it might experience on a farm where the pesticide had been applied, it slept less, and its daily behavioural rhythms were knocked out of synch with the normal 24-hour cycle of day and night."

The fruit fly study published today [21 January] in Scientific Reports, allowed the researchers to study the impact of the pesticides on the insect brain.

As well as finding that typical agricultural concentrations of neonicotinoids ruined the flies' ability to remember, the researchers also saw changes in the clock in the fly brain which controls its 24-hour cycle of day and night.

Dr James Hodge, Associate Professor in Neuroscience in the School of Physiology, Pharmacology and Neuroscience and senior author for the study, added: "Being able to tell time is important for knowing when to be awake and forage, and it looked like these drugged insects were unable to sleep. We know quality sleep is important for insects, just as it is for humans, for their health and forming lasting memories."

Dr Sean Rands, Senior Lecturer in the School of Biological Sciences and co-author, explained: "Bees and flies have similar structures in their brains, and this suggests one reason why these drugs are so bad for bees is they stop the bees from sleeping properly and then being able to learn where food is in their environment.

"Neonicotinoids are currently banned in the EU, and we hope that this continues in the UK as we leave EU legislation."

Papers

Neonicotinoids disrupt memory, circadian behaviour and sleep by Tasman K, Hidalgo S, Zhu B, Rands SA & Hodge JJL in Scientific Reports

The neonicotinoid insecticide imidacloprid disrupts bumblebee circadian rhythms and sleep by Tasman K, Rands SA & Hodge JJL in iScience [open access]

About NeonicotinoidsNeonicotinoids are the most commonly used insecticides in the world and make up nearly 25 per cent of the global insecticide market, which is valued at US $1 billion/year. The intensive use of insecticides has been linked with the global decline in pollinating insects, and all four major types of neonicotinoid have largely been banned in the EU and currently in the UK.

Link:
January: Pesticides and sleep in bees and flies | News and features - University of Bristol